Mark McClellan

Quick Facts

Full Name	Mark McClellan
Occupation	Physician
Date Of Birth	Jun 26, 1963(1963-06-26)
Age	61
Birthplace	Austin
Country	United States
Birth City	Texas
Horoscope	Gemini

Mark McClellan Biography

Mark McClellan is one of the most popular and richest Physician who was born on June 26, 1963 in Austin, Texas, United States. Mark Barr McClellan (born June 26th 1963) is the director of the Robert J Margolis Center for Health Policy and the Margolis Professor of Business, Medicine and Health Policy at Duke University. In the past, he was an associate senior and the director of Health Care Innovation and Value Initiative at the Engelberg Center for Health Care Reform at The Brookings Institution located located in Washington, D.C. McClellan was chief for the United States Food and Drug Administration under the administration of President George W. Bush from 2002 to 2004 and then as the director for the Centers for Medicare and Medicaid Services from 2004 until the year 2006.

In 1997, it was published within The Journal of Economics and Management Strategy McClellan’s article provides a summary and analysis of incentive payments resulting of the Medicare future pay scheme (PPS). In the 1980s, the PPS was designed to motivate hospitals to cut costs by limit the use of costly technology that provided no benefits. The principal feature of PPS is the application of fixed payment through diagnose-related groups (DRGs) in an upcoming manner, that is based on the diagnosis at moment of admission. McClellan believes that the PPS program may not effectively encourage cost sharing between insurers and health professionals due to the income effect that hospitals might seek out specific diagnosis with greater reimbursement rates, similar to skimming in the insurance industry. However retrospective cost sharing permits for the possibility of demand induced by supply which reduces the incentive for hospitals to reduce resource use and the cost of more complex situations.

During 2001 and 2002, McClellan served in the White House. He was a member of the president’s Council of Economic Advisers, where he advised on domestic economic issues. He also served during this time as a senior policy director for health care and related economic issues for the White House.

McClellan served as commissioner for the Food and Drug Administration (FDA) beginning November 14, 2002, becoming the first economist to hold that position. Originally from Austin, Texas, he is the brother of former White House Press Secretary Scott McClellan and the son of Texas comptroller Carole Keeton Strayhorn and attorney Barr McClellan.

The paper presents an economic model that summarizes the reimbursement incentives, provide details on cost sharing and generosity within the PPS model, and analyze what the consequences are of such results. McClellan emphasizes repeatedly how the PPS has allowed more retroactive adjustments to reimbursements. This has been driven primarily by outliers and treatment- driven DRG’s created at the time of admission rather than diagnose-driven DRG’s that were identified prior to admission. Outlier payments permit supplementary payment for particularly long or costly admissions. They are not more than five percent of all hospital admissions. The author considers the rise in the case mix index which measures the quality of care provided and the quality of care provided, to have the greatest impact on the overall PPS payment. He also suggests that retrospective adjustments may affect the effectiveness of the program in the implementation of cost sharing. McClellan’s method allows for specific aspects in PPS that can be analyzed in relation to their impact on costs sharing rates as well as reimbursement variations. He utilized linear regression to determine the way in which cost sharing reimbursement is determined by using variable and fixed components. Costs that were lower resulted in less reimbursements, but greater costs resulted in more reimbursements only when the expenses were triggered by the procedure. This was especially relevant for patients aged 65-69 who had surgeries that required ICU treatment and an extended duration of stay. Estimates of generosity suggest that almost all hospitals have some form of cost sharing. A higher level of generosity is typically linked to higher retrospective limits regarding cost sharing. in the 90s hospitals that were high-tech had higher reimbursed and more likely last while those with a profit motive were less likely leave the market.

Mark McClellan Net Worth

Mark McClellan is one of the richest Physician from United States. According to our analysis, Wikipedia, Forbes & Business Insider, Mark McClellan 's net worth $5 Million. (Last Update: December 11, 2023)

After graduation at the University of Texas in 1985 with a degree in English, Biology, and Plan II and Plan II, he received his M.D. degree from Harvard- MIT’s Division of Technology and Health in 1992. He also earned the Ph.D. in Economics from MIT in the year 1993. He also received an Master of Public Administration degree from the Harvard University Kennedy School of Government in the year 1991. McClellan completed his residency for internal medicine with Brigham and Women’s Hospital, and is board-certified with the field of internal medicine. McClellan’s research projects have focused on the measurement and improvement of the quality of healthcare including the economic and policy aspects that influence the decisions made by doctors and their health outcomes, and estimating the impact of medical treatments and technological advancements in healthcare and the implications on medical and health expenses, and the relation between economic well-being and health. He has received twice an award called the Arrow Award for Outstanding Research in Health Economics.

In sum In summary, in the end, Medicare “Prospective” Payment System has a myriad of retroactive factors which limited cost sharing as of 1990. McClellan’s report is an example of the present attempts to design a health reimbursement system that is based on paying for performance-related criteria, such as penalties for readmissions, and incentives to purchase value-based. In addition, the Patient Protect and Affordable Care Act continues to reinforce the concept of cost sharing by cutting reimbursements within the Inpatient Prospective Payment System.

From 1998 to 1999, McClellan served as deputy assistant secretary of the Treasury for Economic Policy, where he supervised economic analysis and policy development on a wide range of domestic policy issues.

Height, Weight & Body Measurements

Mark McClellan height Not available right now. Mark weight Not Known & body measurements will update soon.

Who is Mark McClellan Dating?

According to our records, Mark McClellan is possibily single & has not been previously engaged. As of December 1, 2023, Mark McClellan’s is not dating anyone.

Relationships Record : We have no records of past relationships for Mark McClellan. You may help us to build the dating records for Mark McClellan!

In 2007, he was appointed as the chair of the Reagan-Udall Foundation, a public-private partnership between the U.S. Food and Drug Administration and industry.

Facts & Trivia

Mark Ranked on the list of most popular Physician. Also ranked in the elit list of famous people born in United States. Mark McClellan celebrates birthday on June 26 of every year.

Is Mark McClellan on the board of Johnson and Johnson?

Former FDA Commissioner, Dr. Mark B. McClellan, to Join Johnson & Johnson Board of Directors | Johnson & Johnson.

When was McClellan FDA commissioner?

11/14/2002 – 3/26/2004* Mark McClellan was sworn in as Commissioner of Food and Drugs on November 14, 2002 , following Senate confirmation by unanimous consent.

Is Dr Mark McClellan married?

A board-certified Internal Medicine physician, Dr. McClellan completed his residency training in internal medicine at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. McClellan is married to Stephanie and has twin five-year old daughters.

Who is Mark Mcclelland?

McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy.

What companies is Scott Gottlieb on the board of directors?

Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. Director Illumina, Inc., Director of Aetion, Inc. a private healthcare data technology company and Tempus, a private technology company. Pfizer Director since 2019.